Introduction
Immunity to viral infections requires both innate and adaptive immune responses. Understanding the induction of such immune responses is a crucial issue in immunology with important implications for vaccine technology. The initiation of an adequate and protective immune response requires the delivery of two signals: one antigen-specific and the other nonantigen-specific. The nonantigen-specific signal involves the costimulatory factors including CD28, CD40, extracellular matrix proteins, early cytokines, such as the type I IFN family constituting IFN-␣/␤, macrophages, DCs and NK cells. [1] [2] [3] [4] [5] These factors orchestrate an adjuvant-like effect on the clonal antigen-specific immune response which includes B, T and NKT cells. Indeed in the absence of the nonantigen-specific signal, the antigen-specific stimulus leads to anergy or apoptosis. Thus the first encounter with antigen facilitates the magnitude and class of the immune response.
A pivotal link between the innate and adaptive immunity is the cytokine family of type I IFN. IFN-␣/␤ has been shown to enhance NK cell cytotoxicity, DC maturation and the cytokines IL-12, IL-15 and IFN-␥ lead- ing preferentially to a Th1 CD4 + T cell response. 6 However, higher doses of IFN-␣/␤ are postulated to inhibit early IFN-␥ production via down-regulation of the high affinity IL-12 receptor and allow the development of a predominant CD8
+ T cell response. 6 Recently, the major source of IFN-␣ was identified as the precursor DC2. 7 The incorporation of IFN subtypes in viral vaccination may improve the adjuvant capacity of the vaccine and provoke more protective and longer-lasting immunity. 8 The role of various IFN-␣ subtypes in health and disease will promote our understanding of the interface between innate and adaptive immunity and aid clinical investigations into potent biotherapeutics.
Cytomegalovirus (CMV) causes latent, persistent and recurring infections in immunocompromised or immunosuppressed individuals with various disease sequelae including pneumonitis, 9 hepatitis, 10 mononucleosis, 11 and myocarditis. 12, 13 Active CMV infection has been associated with higher rates of severe allograft rejection and cardiac dysfunction, in heart transplant recipients and patients with AIDS, respectively. 14, 15 Heart transplant recipients experiencing a primary CMV infection during transplantation have a 46% incidence of developing myocarditis, 16 while 50-65% of patients with active myocarditis have been found to be positive for CMV DNA in heart tissues. 17 In addition, myocardial damage post-CMV infection may persist in immunocompromised patients and lead to dilated cardiomyopathy. 18 If the host develops cross-reactive antiviral immune responses to tissue antigens, autoimmune disease may be established. Thus, virus infection is a trigger for post-viral autoimmune mechanisms in the pathogenesis of autoimmune disease. 19 We have characterised a murine model for CMVinduced myocarditis. 20 Although replicative virus in the heart is not detected beyond day 10, BALB/c mice develop chronic myocarditis in the absence of infectious virus in the heart. A cellular cardiac infiltrate composed of polymorphonuclear neutrophils, macrophages and mononuclear lymphocytes, predominantly CD8 + T cells, is observed within 3 days reaching a peak at 7 days after infection. The chronic phase of myocarditis is characterised by a diffuse cellular infiltrate, which is maintained for at least 100 days after infection. During the chronic phase of the disease, pathogenic autoantibodies to the cardiac isoform of myosin are produced. [21] [22] [23] Thus the disease process is multifactorial.
It is well accepted that the direct delivery of antigenic proteins as DNA into muscle leads to cytosolic synthesis and presentation of antigen which can induce both humoral and cellular immune responses. To compare the specific roles of IFN subtypes as costimulatory cytokines for immune induction in a CMV murine model, we constructed plasmid DNAs expressing IFN-alpha 6, IFNalpha 9 and IFN-beta, 24 coimmunised mice with the IFN plasmid and the gB DNA plasmid vaccine, and then analysed immunomodulatory effects in vivo. We demonstrate that DNA encoding IFN-gene cassettes when coinoculated with the gB DNA vaccine provides better protective immunity against CMV infection in mice than gB DNA alone.
IFN DNA coimmunisation was shown to regulate antiviral antibody production and circulating cytokine levels of TNF and IL-10. We show significantly decreased levels of inflammation in the heart in mice infected with MCMV and immunised with IFN DNA in combination with gB DNA. Furthermore, T cells from MCMV-infected mice can transfer disease to uninfected recipients. However, T cells from IFN DNA-immunised mice induce less severe disease upon in vivo transfer. These results taken together suggest that IFN-A6, -A9 and -B may enhance antigenic stimulation of both B and T cells in the immune response against a herpesvirus infection. Thus interferons show strong potential in immunomodulatory gene therapy for improved efficacy of viral vaccines.
Results

Molecular design of IFN and gB DNA constructs
Sequence analysis of the gB gene from the Perth-derived K181 strain of MCMV revealed a seven amino acid difference in homology from the Smith strain: aa 806 to 812, RQRSAAA. This viral gene was cloned into the mammalian expression vector pkCMVint consisting of a HCMV IE-promoter/enhancer and HCMV intron A for activation of transcription in skeletal muscle. The three type I IFN genes investigated, IFN-A6, -A9 and -B were chosen due to previous findings of their strong capacity to either reduce MCMV titres or MCMV-induced myocarditis in the murine model. 24 The IFN genes were cloned within 20 nucleotides of the start and stop codons for increased stability and expression of transcripts (Figure 1a ). RNA transcripts produced by transfected COS-7 cells were confirmed to be similar in expression levels for the transfected gene by Northern analysis (Figure 1b) . Furthermore, protein expression of gB from transfected COS-7 cells was confirmed by immunoblot ( Figure 1c) . Following in vivo gene transfer into skeletal muscle, levels of IFN transgene expression as determined by IFN bioassay, ranging from 1.2-2.0 × 10 4 IU/g, were detected in the TA muscle at day 7 after inoculation of BALB/c mice (Figure 1d ).
Viral titre reduction in gB CMV DNA-vaccinated mice coinjected with IFN-A9/B
To examine the capacity of type I IFN to enhance protection afforded by the viral gB DNA vaccine, BALB/c mice were co-injected with plasmid constructs for either IFN-A6, IFN-A9, or IFN-B 2 weeks before viral challenge with 10 4 p.f.u. MCMV. Early replication of MCMV in both the spleen and liver at day 3 p.i. was first examined. CMV gB given alone caused a slight decrease in splenic viral titres (Figure 2a ), but did not reduce liver viral titres ( Figure 2b ) compared with viral titres obtained from control mice injected with the blank expression vector. However, mice coimmunised with gB and either IFN-A9 or IFN-B displayed significantly reduced viral titres in the spleen and liver, below the level of detection, compared with gB DNA-vaccinated mice. In contrast, mice that received gB and IFN-A6, showed significantly increased splenic viral titres, however, no significant reduction was observed for the liver viral titres compared with mice vaccinated with gB alone. This indicated that reduction of MCMV replication in both the spleen and liver was enhanced by coimmunisation of select IFN subtypes, namely IFN-A9 and IFN-B with the gB viral vaccine. Mice inoculated with either IFN-A9 or IFN-B alone did not show significantly reduced virus titres in the spleen or liver. 24 Next we examined the level of viral replication in the salivary glands at day 7 p.i., the initial phase of persistent MCMV infection in this tissue. Neither the gB vaccine alone nor any combination with the co-injected IFN subtypes was capable of reducing viral titres in the salivary glands ( Figure 2c ). Our previous studies showed no effect of either IFN-A9 or IFN-B DNA alone on virus replication in this organ. 24 Thus our DNA vaccine approach had limited effect at inhibiting both viral tropism and MCMV replication in this organ. Since it is known that CD4 + T cell responses control CMV replication in the salivary glands, the DNA vaccination approach may not be favourable for protection in this organ.
Antiviral Ig production in IFN and gB DNA vaccinated mice Antiviral Ig production in the sera, determined by ELISA, was found to be predominantly IgG1 ( Figure 3 ). Mice vaccinated with gB DNA produced IgG antibodies to MCMV. Viral gB DNA vaccinated mice coimmunised with IFN-B showed a significantly higher level of antiviral IgG1 and IgG2a production compared with mice vaccinated with gB alone. In contrast, mice coimmunised with IFN-A6 showed reduced levels of antiviral IgG1 and IgG2a. No change in antibody production was observed for mice coinjected with IFN-A9 and gB vaccine at 1 week post-challenge with MCMV. Interestingly, immune sera from all mice coimmunised with gB showed reactivity to both the surface 105 kDa and transmembrane 52 kDa sub-
Figure 1 gB glycoprotein and type I IFN DNA constructs and detection of expression. (a) Sequence specification of gB and type I IFN DNA gene cassettes inserted into the mammalian expression vector pkCMV.int polylinker. (b) gB and IFN-A/B mRNA expression in COS-7 cells transfected with the plasmid constructs and hybridised to gB, IFN-A1 or IFN-B specific probes as designated. (c) Cell lysates (100 g), from COS-7 cells transfected with either blank (control vector without IFN gene insert) or gB DNA constructs, electrophoresed using 10% tris-glycine gels by SDS-PAGE, and immunoblotted with hyperimmune sera (HIS) from MCMV-infected BALB/c mice. Arrows show MW of predominant gB subunits, 105 and 52KDa reactive with antibodies (d) In vivo expression of type I IFN transgenes in TA muscle of DNA-vaccinated mice 7 days after MCMV infection as determined by IFN bioassay. Error bars represent standard error of the mean ( * significance to blank P Ͻ 0.05, n = 5).
units of gB by immunoblot. However, control mice only displayed antibody reactivity to the 105 kDa subunit (data not shown).
Mice treated with DNA without MCMV challenge were also investigated at day 14 after DNA expression for circulating antiviral antibodies by ELISA. Control groups injected with saline without DNA did not show any detectable anti-MCMV antibodies in the sera. Mice inoculated with the gB DNA alone did not produce detectable anti-viral antibodies. However, mice treated with gB/IFN-B DNA had significantly increased antiviral IgG1 antibody titres against MCMV (4.8 ± 0. 
Circulating cytokine levels in IFN and gB DNAvaccinated mice
The circulating levels of the Th1 cytokine IFN-␥, Th2 cytokines IL-4 and IL-10, and the proinflammatory cytokines TNF and IL-6 in gB and IFN DNA-vaccinated mice was next examined. Mice coimmunised with either IFN-A6, IFN-A9 or IFN-B and the gB vaccine were examined for the production of circulating IFN-␥, IL-4, IL-10, IL-6 and TNF in the sera at day 3 p.i. Viral gB DNA treatment alone caused a dramatic decrease in serum IL-4 levels and also moderately reduced IL-6 levels, however, no change was observed in IFN-␥, IL-10 or TNF levels ( Figure 4) . IFN-A6 coimmunisation significantly increased IL-4, IL-10 and TNF levels compared with gB alone (Figure 4b, c, e) . IFN-A9 coimmunisation signifi- cantly increased IL-4, IL-10 and TNF levels (Figure 4b , c, e), and did not alter serum IL-6 compared with gB vaccination (Figure 4d ). IFN-B coimmunisation diminished IFN-␥ levels by 65% (Figure 4a ). Furthermore, IL-4 and TNF levels were increased by IFN-B co-injection ( Figure  4b , e). IL-2 was not detected in the sera at day 3 p.i. of any groups of mice immunised with either gB or in combination with IFN DNA plasmids.
Based on these results, we predict that T cell stimulation is differentially regulated by the individual IFN subtypes. IFN-␥ responses appear to be down-regulated by IFN-B in gB-vaccinated mice. IL-4 production is restored by IFN-A6 or IFN more, IL-6 production is up-regulated by IFN-A6, but not by IFN-A9 and IFN-B. This is consistent with the opposing antiviral effects of these IFN subtypes observed in the spleen. Interestingly, all IFN subtypes increased early TNF production.
IFN and gB DNA coimmunisation affects acute myocarditis
Biphasal myocarditis develops following MCMV-infection of BALB/c mice. 20 Next we investigated whether IFN and gB DNA coimmunisation afforded improved protection against the development of acute myocarditis following MCMV infection.
Myocarditis characterised by inflammatory foci and necrosis in the myocardium was evaluated at day 7 p.i. (Figure 5 ). gB vaccination alone reduced the level of acute myocarditis compared with blank vector used in the control mouse group. We found that mice coinjected with either IFN-A9 or IFN-B and gB DNA had significantly reduced severity of myocarditis at day 7 p.i. compared with mice vaccinated with blank DNA alone and chal- lenged with MCMV (Figure 5a ). In contrast, acute myocarditis levels in mice coimmunised with either IFN-A6 or IFN-A9 and gB were undiminished compared with gB vaccination alone, while gB/IFN-B vaccination verged on significance (P Ͻ 0.06). From these findings it is reasonable to deduce that a reduced viral load during the early phase of replication can abate the subsequent development of acute phase myocarditis. Splenic virus load was reduced by coimmunisation of either IFN-A9 or IFN-B with gB, whereas IFN-A6 treatment enhanced splenic viral replication and did not cause any alteration to the severity of acute inflammation in the heart. However, virus titres do not reach high levels in the heart of MCMV-infected mice and virus-infected myocytes do not always colocalize to foci of cardiac inflammation. 20 
Chronic myocarditis and autoantibodies in the autoimmune phase post-infection
The effect of coimmunisation of IFN subtypes with viral gB DNA vaccine on the progression of chronic myocarditis in mice challenged with MCMV was characterised at days 30 and 56 p.i. (Figure 6 ). Vaccination with gB DNA Gene Therapy slightly reduced the chronic levels of myocarditis. Mice coinjected with either IFN-A6, -A9 or -B significantly suppressed inflammation in the heart at both late timepoints. However, coimmunisation with IFN-B induced the greatest level of protection from myocarditis.
During the chronic phase of myocarditis, autoimmunity develops with the production of anti-heart and anticardiac myosin Igs. 21 Vaccination with gB reduced the levels of IgG1 and IgG2a antibodies reactive with heart extract at day 30 p.i. (Figure 7a ). However, none of the IFN subtypes significantly reduced the level of heart autoantibodies below the titres produced in gB-vaccinated mice following virus infection (with the exception of IgG1 and IFN-A6 coimmunisation). A strong autoantibody response to cardiac myosin is generated in MCMVinfected mice. Vaccination with gB DNA did not change the anti-cardiac myosin antibody titres (Figure 7b ). However, anti-cardiac myosin IgG1 titres were shown to be significantly enhanced in IFN-B coimmunised mice, whereas IgG2a titres were significantly reduced with IFN-A6 and IFN-A9 coimmunisation compared with mice vaccinated with gB alone (Figure 7b ). 
u. MCMV i.p. Hearts were removed at day 7 p.i. and fixed in Bouin's fluid, processed as paraffin-embedded blocks, sectioned and stained with H&E. Myocarditis (a) was scored as the average number of inflammatory foci per heart section. Data are representative of two independent experiments (n = 5 for each independent experimental group). Error bars represent standard error of the mean ( * significance to blank, P Ͻ 0.05). Heart sections from blank (b), gB (c), gB/IFN-A6 (d), gB/IFN-A9 (e), and gB/IFN-B (f) DNA-inoculated mice showing representative foci of cellular infiltrates characteristic of acute myocarditis. Original magnification ×40.
T cells from MCMV-infected mice transfer myocarditis to uninfected mice
Next we examined the pathogenic role of T cells in myocarditis following MCMV infection, since it has been established that T cells are critical for the disease. 25, 26 Splenic T cells from mice, inoculated with blank vector and infected with MCMV for 5 days, transferred disease to uninfected syngeneic mice (Figure 8 ). Splenocytes, from mice inoculated with either IFN-B or IFN-A6 DNA and allowed to express the IFN transgene for 14 days before MCMV infection, were transferred to uninfected recipients. Reduced myocarditis was found in the hearts of mice injected with splenocytes from the IFN-B-treated mice, but not from IFN-A6-treated mice, at day 7 after transfer. Thus IFN-B treatment appeared to affect the T cell regulation of the cardiac disease.
Discussion
The delivery of antigenic epitopes in the context of a DNA plasmid vaccine leads to intracellular processing of the transgene product and the induction of both humoral and cellular immune responses. Design and synthesis of mammalian expression vectors to modulate the immune response is a desired goal in vaccine technology. In this study, we demonstrate that the efficacy of viral DNA vaccination can be improved with coinjection of type I IFN DNA using a murine model of CMV infection and cardiac disease. We report that persistent expression of select IFN transgenes in vivo was effective at reducing virus titres in the spleen and liver following challenge of gB DNA-vaccinated mice with virulent MCMV. Coimmunisation with either IFN-A9 or IFN-B plasmids was superior to IFN-A6 plasmid. The reduction in viral load was reflective in an enhanced antiviral IgG antibody response for IFN-B-vaccinated mice. Cytokine production was also influenced by IFN coimmunisation. IFN-B coimmunisation markedly suppressed IFN-␥ production and increased IL-4 and TNF production. Furthermore, the development of acute viral myocarditis was inhibited with either IFN-A9 or IFN-B coimmunisation. We also report the effects of gB vaccination with IFN on the progression to autoimmune chronic myocarditis. IFN-B coimmunisation was shown to be most efficacious in suppressing both heart inflammation and IgG2a cardiac autoantibodies. Furthermore, IFN-B-treated mice regulate T cell-dependent myocarditis. Overall, IFN-B coimmunisation was superior to the other IFN subtypes in facilitating a protective immune response. Thus the results presented here imply that the type I IFN, a key product Gene Therapy of the innate immune response, regulates the development of humoral and cellular immunity in virus infection.
Local production, level and timing of cytokine expression are important in the induction of the type of class of immunity. Recent work has shown MCMV to be a poor inducer of type I IFN with low doses of IFN endogenously produced during infection. 6 Normally, this low concentration of type I IFN leads to immunoregulatory effects encompassing induction of NK cell cytotoxicity, augmentation of IL-12 effects and promotion of Th1 CD4 + T cell responses. 6 However, IFN transgene expression levels, via further cytokine networks, may elevate antiviral pathways leading to inhibition of IL-12 expression and NK cell production of IFN-␥ which will enhance preferentially CD8 + T cell responses. Indeed, we have recently shown manipulation of anti-MCMV immune responses with use of type I IFN DNA expression in vivo. 24 Type I IFN has been shown to affect B cells, enhancing IgM, IgG2a and IgA antibody production. 27 The envelope glycoproteins of CMV are important antigenic targets for the immune response. Neutralising antibody responses are predominantly directed against the most abundant and highly conserved surface glycoprotein, gB, making it a valid candidate for inclusion in a viral vaccine. The 160 kDa precursor protein for HCMV gB is cleaved into two subunits: surface gp116 and transmembrane gp58, and contains at least seven neutralising epitopes. 28, 29 In MCMV, B cell epitopes occur in three regions of gB corresponding to amino acid residues 17-70, 155-278 and 809-926 and the molecule has two subunits; 105 kDa and 52 kDa. 30 The transmembrane domain of gB (52 kDa) is involved in attachment of the virus to heparin cell receptors and mediates cell fusion. 31 Here we report that the antibody response elicited by gB with IFN-B enhanced antiviral IgG2a and IgG1 antibody responses with little enhancement from the IFN-A6 and IFN-A9 subtypes. Conflictingly, other workers have reported a moderate increase in antibody response with HCMV gB DNA vectors coimmunized with IFN-␣, presumably recombinant IFN-␣, in a mouse model. 32 We postulate that use of other IFN subtypes would alter the antiviral antibody response.
Costimulation of T cells is also a critical determinant in immune activation in combating a viral infection. Cytokine production was characterised in this study as a signalling component of paramount importance in the cellular immune response. Interestingly, IFN-␥ production was found to be differentially regulated by individual type I IFN subtypes. As found previously with IFN-A6 DNA immunisation, IFN-␥ levels are increased with gB/IFN-A6 coimmunisation. 24 Whereas, mice coimmunised with IFN-A9 or IFN-B showed reduced IFN-␥ production. Other workers have found that low levels of IFN-␥ reduce myocarditis, whereas high levels increase lethality to MCMV infection. 33 In addition, the proinflammatory cytokines TNF and IL-6 showed differential regulation via IFN treatment in our model. IL-6 overexpression can lead to suppression of TNF production over time and increased myocarditis, perhaps explaining the lesser effects of the IFN-A6 subtype. 34 Alternatively, other workers have engineered gene therapy vectors to express the CD40L molecule as a means to activate T cells in a gD DNA vaccination approach for HSV-2 infection in mice. 35 They observed higher IgG2a and IFN-␥ responses suggestive of a drive towards Th1 phenotype and enhanced protection by CD40L plasmid coinjection in HSV-2-challenged mice. CD40L was also shown to promote CD4 + T cell migration to the DNA-inoculated muscle sites. Improving vaccine design for CD8 T cell epitopes on the immunodominant immediate-early protein 1 (ie-1) of CMV may also provide important knowledge in generating protective and long-lasting immunity. 36 Indeed a combination of viral gB and ie-1 gene products with coimmunisation of type I IFN may provide synergy towards mounting complete protection against infectious CMV.
The pleiotropic properties of the type I IFNs give rise to various biological functions, including regulation of the immune response. DNA vaccination may be used for the treatment of autoimmune disease. Induction of protective immunity steered towards the immunodominant viral epitopes through gB vaccination may shift the balance away from the induction of autoreactivity. In addition, activation of T cells with gB/IFN vaccination may regulate the immune response and assist in the avoidance of the development of autoimmunity. 37, 38 MCMV-induced chronic myocarditis is autoimmune in nature and is mediated, in part, by T cells and antibody to cardiac myosin. 21, 25, 26 Control of myocarditis via the actions of regulatory T cells on pathogenic autoreactive cells is a potential process for immunomodulation. In this study, we demonstrate that adoptive transfer of T cells from IFN-B DNA-inoculated mice infected with MCMV can reduce myocarditis. Potential IFN mechanisms of action include the effects of regulatory T cells, memory CD8 + T cells, apoptosis and proliferation of T cells. Type I IFNs have been shown to induce the proliferation of memory CD8
+ T cells via IL-15. 39 IFN also prevents apoptosis and may contribute to the persistence of immunological memory. 40 Other workers have noted that dysregulated concentrations of IFN production in disease may cause inappropriate inhibition of T cell proliferation. 41 Elucidation of the immunomodulatory links of the innate with the adaptive immune response are therefore under detailed investigation. The restrictive use of either a single IFN-alpha subtype, recombinant IFN or IFN-␣/␤ mixture in these experiments makes interpretation of specific T cell effects difficult to ascertain. Our data indicate suppression of T cell responses in the development of myocarditis with IFN-B treatment. This is consistent with our findings that CD8 + T cells are the major infiltrating cell type in the myocarditic heart. 42 In this article, we describe the facilitation of the immune response to virus with DNA vaccination designed to include select type I IFNs. These studies demonstrate that type I IFNs play an important role in modulating protective antigen-specific immune responses. Overall, the effects of type I IFN in vaccination, either working directly or indirectly with cells of the adaptive immune response, provide an opportunity for orchestration of the elicited immune response. Further studies into the effects of such IFN DNA coimmunisation on the longevity and memory of the protective immune response elicited by the gB DNA vaccine need to be conducted. In conclusion, the potential strategic use of plasmid IFN DNA injected into muscle for consistent secretion of protein as a natural adjuvant may underpin success for viral vaccination.
Materials and methods
Mice
Specific pathogen-free 6-week-old male BALB/c mice were used (Animal Resources Centre, Murdoch, Western Australia). All animal experiments were conducted according to the Guidelines for Animal Experimentation, National Health and Medical Research Council, Australia.
Cytomegalovirus
The K181 strain of MCMV was originally obtained from D Lang (Duke University, Durham, NC, USA) and prepared as a salivary gland homogenate from virusinfected weanling BALB/c mice, as detailed previously. 21 Virus titres in infected mice were quantitated by plaque assay using M2-10B4 stromal cells and calculated as mean p.f.u./g tissue. The limit of detection for the plaque assay was 100 p.f.u./g spleen and liver and 6400 p.f.u./g for salivary glands. Virus was diluted in pyrogen-free saline and injected intraperitoneally (10 4 p.f.u./mouse).
Plasmid constructs and DNA vaccination
The mammalian expression vector, pkCMVint, was generously provided by VICAL (San Diego, CA, USA) and contained the HCMV IE-1 promoter/enhancer element and intron A with the SV40 polyadenylation signal. The MCMV gB gene, 2874 bp fragment, from pBR322.gB (generously provided by T Scalzo, University of Western Australia), was subcloned into the BamHI site of the expression vector. Three individual IFN constructs were made with either the murine IFN-alpha 6, IFN-alpha 9, or IFN-beta gene inserts including the 69 nucleotide signal sequence upstream of the first cysteine codon. 24 Fragments cloned were IFN-A6 -24 to + 590 bp, IFN-A9 -25 to + 595 bp, and IFN-B -10 to + 599 bp. All inserts were sequenced in both directions to ensure complete integrity. Large-scale plasmid preparations were obtained from terrific broth cultures of transformed E. coli (DH-5␣) using standard DNA extraction procedures with LiCl precipitation. 'Blank' refers to the vector, pkCMVint without the IFN or gB gene insert, used to inoculate mice in control groups.
DNA plasmids were injected into regenerating tibialis anterior muscle. Mice were inoculated with 100 g of each construct in pyrogen-free saline. Two weeks after DNA inoculation, mice were infected with MCMV (10 4 p.f.u./mouse).
Transfections
Transfection with the IFN plasmids was performed as previously described. 43 Briefly, COS-7 cells were transfected with calcium phosphate precipitated DNA. After 24 h, the supernatant was collected and acid-treated (pH 2.0) to remove acid labile proteins.
Northern hybridisation
Total cellular RNA extracted from the transfected COS-7 cells using Trizol was electrophoresed using a formaldehyde denaturing gel and hybridised to 32 P-labelled cDNAs encoding gB (521 bp fragment from K181 MCMV), IFN-B subtype (577 bp; XbaI/SalI fragment from construct) and IFN-A1 subtype (553 bp; BamHI/BglII fragment from construct).
IFN bioassay
Standard murine type I IFN (Lee Biomolecular, CA, USA) and test samples were used in a bioassay for quantitation of acid-stable IFN expressed as 50% protection from EMCV-induced CPE of L929 cell monolayers (IU/ml or IU/g) as described previously. 44 
Myocarditis histology
Hearts were transected along the midline, fixed in Bouin's fluid and processed as paraffin-embedded blocks before stained with H&E. Heart sections were scored for myocarditis as the number of inflammatory foci observed for each section over approximately eight fields of view (magnification ×40). Two sections per heart and five mice per independent experimental group were recorded. The average score of myocarditis ± s.e. is shown.
SDS-PAGE
SDS-PAGE was performed with transfectant samples electrophoresed using 10% Tris-HCl gels (Bio-Rad, Hercules, CA, USA), transferred to nitrocellulose membrane and blotted with hyperimmune sera against MCMV (preabsorbed with COS-7 cell extract) and then antimouse IgG horseradish peroxidase. Enhanced chemiluminescence was performed and the protein reactivity detected by exposure to Hyperfilm (Amersham Pharmacia Biotech, Buckinghamshire, UK).
ELISA MCMV antigen, murine heart homogenate, and murine cardiac myosin were used as coating antigens in the ELISA as previously described. 21 Titres are expressed as log2 serum antibody titre ± s.e. The cytokines IFNgamma, IL-4, IL-6, TNF and IL-10 were quantitated in the sera using ELISA kits (OptEIA ELISA, Pharmingen, San Diego, CA, USA).
T cell transfer BALB/c mice were treated with bupivacaine and inoculated with either blank, IFN-A6 or IFN-B DNA (200 g/mouse) in the TA muscles as previously described. After 14 days, mice were challenged with MCMV (10 4 p.f.u./mouse) by the i.p. route and following 5 days p.i., spleens were harvested. Splenocyte cell suspensions (9 × 10 6 cells) were injected intravenously into uninfected BALB/c mice. At day 7 following T cell transfer, hearts were removed and processed for histological examination of myocarditis.
Statistical analysis
Results are means ± s.e. Unpaired Student's t test assuming unequal variance between the means was used to determine levels of significance (P values less than 0.05).
